Beckman Coulter has announced US Federal Drug Administration approval for the Access soluble transferrin receptor (sTfR) assay and the sTfR/log ferritin index (sTfR index) as an aid in the diagnosis of iron-deficiency anaemia (IDA) and the differential diagnosis of anaemia of chronic disease (ACD) from IDA, with or without ACD.
The automated sTfR assay and the sTfR index, which is calculated onboard Beckman Coulter’s Access and UniCel DxI instruments, produces a recommended cut-off that can indicate the nature of a patient’s anaemia. The cut-off can assist in determining the best course of treatment, especially for the chronically ill. Together, the Access sTfR assay and sTfR index are new and important diagnostic tools that aid in diagnosis and simplify the complex aetiology of anaemia.
Soluble transferrin receptor is intended (with other indicators of iron status) as an aid in the diagnosis of IDA, especially in patients with chronic disease. Beckman Coulter offers an array of diagnostic tools in chemistry, haematology and data management that, when used in conjunction with the Access sTfR assay, provide a comprehensive diagnostic solution for anaemia disease management.
www.beckmancoulter.com